Page 79 - AN-4-2

Advanced Neurology Brain bioavailability of targeted protein degraders

brain barrier: Nanomedicine for glioblastoma multiforme. of the importance of organic anion transporters (OATs) in
Drug Deliv Transl Res. 2020;10(2):304-318. drug therapy. Handb Exp Pharmacol. 2011;201:29-104.
doi: 10.1007/s13346-019-00679-2 doi: 10.1007/978-3-642-14541-4_2
33. Kealy J, Greene C, Campbell M. Blood-brain barrier 44. Ballabh P, Braun A, Nedergaard M. The blood-brain barrier:
regulation in psychiatric disorders. Neurosci Lett. An overview: Structure, regulation, and clinical implications.
2020;726:133664. Neurobiol Dis. 2004;16(1):1-13.
doi: 10.1016/j.neulet.2018.06.033 doi: 10.1016/j.nbd.2003.12.016
34. Pulgar VM. Transcytosis to cross the blood brain barrier, new 45. Wilhelm I, Nyúl-Tóth A, Suciu M, Hermenean A, Krizbai IA.
advancements and challenges. Front Neurosci. 2019;12:1019. Heterogeneity of the blood-brain barrier. Tissue Barriers.
2016;4(1):e1143544.
doi: 10.3389/fnins.2018.01019
doi: 10.1080/21688370.2016.1143544
35. Khan AR, Liu M, Khan MW, Zhai G. Progress in brain
targeting drug delivery system by nasal route. J Control 46. Brown PD, Davies SL, Speake T, Millar ID. Molecular
Release. 2017;268:364-389. mechanisms of cerebrospinal fluid production. Neuroscience.
2004;129(4):957-970.
doi: 10.1016/j.jconrel.2017.09.001
doi: 10.1016/j.neuroscience.2004.07.003
36. Pardridge WM. Drug transport across the blood-brain
barrier. J Cereb Blood Flow Metab. 2012;32:1959-1972. 47. Schilde LM, Kösters S, Steinbach S, et al. Protein variability
in cerebrospinal fluid and its possible implications for
doi: 10.1038/jcbfm.2012.126
neurological protein biomarker research. PLoS One.
37. Møllgård K, Dziegielewska KM, Holst CB, Habgood MD, 2018;13(11):e0206478.
Saunders NR. Brain barriers and functional interfaces with
sequential appearance of ABC efflux transporters during doi: 10.1371/journal.pone.0206478
human development. Sci Rep. 2017;7(1):11603. 48. Joan Abbott N. Evidence for bulk flow of brain interstitial
fluid: Significance for physiology and pathology. Neurochem
doi: 10.1038/s41598-017-11596-0
Int. 2004;45(4):545-552.
38. Sharma G, Sharma AR, Lee SS, Bhattacharya M, Nam JS,
Chakraborty C. Advances in nanocarriers enabled brain doi: 10.1016/j.neuint.2003.11.006
targeted drug delivery across blood brain barrier. Int J 49. Cserr HF, Cooper DN, Suri PK, Patlak CS. Efflux of
Pharm. 2019;559:360-372. radiolabeled polyethylene glycols and albumin from rat
brain. Am J Physiol. 1981;240(4):F319-F328.
doi: 10.1016/j.ijpharm.2019.01.056
doi: 10.1152/ajprenal.1981.240.4.F319
39. Durant ST, Zheng L, Wang Y, et al. The brain-penetrant
clinical ATM inhibitor AZD1390 radiosensitizes and 50. Cserr HF, Patlak CS. Secretion and bulk flow of interstitial
improves survival of preclinical brain tumor models. Sci fluid. In: Physiology and Pharmacology of the Blood-Brain
Adv. 2018;4(6):eaat1719. Barrier. New York: Springer; 1992. p. 245-261.
doi: 10.1126/sciadv.aat1719 doi: 10.1007/978-3-642-76894-1_9
40. Urquhart BL, Kim RB. Blood-brain barrier transporters 51. Dolman D, Drndarski S, Joan Abbott N, Rattray M.
and response to CNS-active drugs. Eur J Clin Pharmacol. Induction of aquaporin 1 but not aquaporin 4 messenger
2009;65(11):1063-1070. RNA in rat primary brain microvessel endothelial cells in
culture. J Neurochem. 2005;93(4):825-833.
doi: 10.1007/s00228-009-0714-8
doi: 10.1111/j.1471-4159.2005.03111.x
41. Gao B, Stieger B, Noé B, Fritschy JM, Meier PJ. Localization
of the organic anion transporting polypeptide 2 (OATP2) in 52. Pardridge WM. CSF, blood-brain barrier, and brain drug
capillary endothelium and choroid plexus epithelium of rat delivery. Expert Opin Drug Deliv. 2016;13(7):963-975.
brain. J Histochem Cytochem. 1999;47(10):1255-1264.
doi: 10.1517/17425247.2016.1171315
doi: 10.1177/002215549904701005
53. Reiber H, Felgenhauer K. Protein transfer at the blood
42. Ose A, Kusuhara H, Endo C, et al. Functional characterization cerebrospinal fluid barrier and the quantitation of the
of mouse organic anion transporting peptide 1A4 in the humoral immune response within the central nervous
uptake and efflux of drugs across the blood-brain barrier. system. Clin Chim Acta. 1987;163(3):319-328.
Drug Metab Dispos. 2010;38(1):168-176.
doi: 10.1016/0009-8981(87)90250-6
doi: 10.1124/dmd.109.029454
54. Fishman RA, Christy NP. Fate of adrenal cortical steroids
43. Burckhardt G, Burckhardt BC. In-vitro and in-vivo evidence following intrathecal injection. Neurology. 1965;15:1-6.

Volume 4 Issue 2 (2025) 73 doi: 10.36922/an.5140